CoChat

Raising the Minimum Effective Dose of Serotonin Reuptake Inhibitor Antidepressants: Adverse Drug Events

Safer, Daniel J. · 2016 · Journal of Clinical Psychopharmacology

The DOI matches its Crossref record; 185 of the 185 references it cites were found in a registry or an index.

Abstract

This review focuses on the dose-response of serotonin reuptake inhibitor (SRI) antidepressants for efficacy and for adverse drug events (ADEs). Dose-response is identified by placebo-controlled, double-blind, fixed-dose clinical trials comparing various doses for efficacy and for ADEs. Reports from the great majority of clinical trials have consistently found that the minimum SRI effective dose is usually optimal for efficacy in the treatment of depression disorders, even though most American medical practitioners raise the dose when early antidepressant treatment results are negative or partial. To better understand this issue, the medical literature was comprehensively reviewed to ascertain the degree to which SRI medications resulted in a flat dose response for efficacy and then to identify specific ADEs that are dose-dependent. Strong evidence from fixed-dose trial data for the efficacy of nonascendant, minimum effective doses of SRIs was found for the treatment of both major depression and anxiety disorders. Particularly important was the finding that most SRI ADEs have an ascending dose-response curve. These ADEs include sexual dysfunction, hypertension, cardiac conduction risks, hyperglycemia, decreased bone density, sweating, withdrawal symptoms, and agitation. Thus, routinely raising the SRI dose above the minimum effective dose for efficacy can be counter-productive.

Overview

Integrity signals

Registry

Crossref · 10.1097/jcp.0000000000000564

Cites

185 of 185 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 185 references

Research works printed but not linked: 5

  1. 2014, Levomilnacipran inhibits both norepinephrine and serotonin reuptake across the clinical dose range, Eur Neuropsychopharmacol, 24, S459
  2. 1992, Serotonergic antidepressants and their efficacy in obsessive compulsive disorder, J Clin Psychiatry, 53, 56
  3. 2014, Effect of SSRIs on bone metabolism, Encephale, 40, 56
  4. 1990, Fluoxetine: relationships among dose, response, adverse events, and plasma concentrations in the treatment of depression, Psychopharmacol Bull, 26, 18
  5. 1983, Clinical evaluation and natural course of depression, J Clin Psychiatry, 44, 5

Cited by

See all 19

Metadata

Authors
Safer, D. J.
Affiliations
Johns Hopkins University (US)
Corresponding author
Safer, Daniel J.
Venue
Journal of Clinical Psychopharmacology
Published
2016-10
Volume
36
Issue
5
Pages
483-491
ISSN
  • 0271-0749 (ISSN-L)
  • 1533-712X
OpenAlex
W2518204736
Cited by
19
References
185
Citations by year
2026: 2 · 2025: 1 · 2024: 1 · 2023: 2 · 2022: 1 · 2021: 4 · 2020: 1 · 2019: 3 · 2018: 1 · 2017: 3
FWCI
0.27
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Clinical Psychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
  • Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
Keywords
serotonin reuptake inhibitors, minimum effective dose, dose escalation, adverse drug reactions, depression, anxiety disorders, sexual dysfunction, hypertension, cardiac conduction, hyperglycemia, bone mineral density, withdrawal symptoms, agitation
MeSH terms
Dose-Response Relationship, Drug, Humans, Selective Serotonin Reuptake Inhibitors, Drug-Related Side Effects and Adverse Reactions

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Raising the Minimum Effective Dose of Serotonin Reuptake Inhibitor Antidepressants: Adverse Drug Events. https://app.cochat.ai/papers/10.1097/jcp.0000000000000564
The paper
Safer, D. J. (2016). Raising the Minimum Effective Dose of Serotonin Reuptake Inhibitor Antidepressants: Adverse Drug Events. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/jcp.0000000000000564

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.